Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Mesalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Mesalazine Dr Falk Pharma suppositories contain the active substance mesalazine, an antiinflammatory agent used to treat inflammatory bowel disease. Mesalazine Dr Falk Pharma suppositories are used for: − the treatment of mild and moderate episodes of an inflammatory disease in the rectum (back passage) known by doctors as ulcerative colitis or ulcerative proctitis.
e Mesalazine Dr Falk Pharma 500 mg suppositories Do not use Mesalazine Dr Falk Pharma suppositories − If you are allergic to salicylic acid, to salicylates such as acetylsalicylic acid (e.g., aspirin) or to any of the other ingredients of this medicine (listed in section 6).
During treatment your doctor may want to keep you under close medical supervision and you may need to have regular blood and urine tests. Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine. Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4. If you experience strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears contact your doctor immediately. Other medicines and Mesalazine Dr Falk Pharma suppositories Tell your doctor or pharmacist if you are taking, have recently taken or might take any of the medicines mentioned below as the effects of these medicines may change (interactions): − Certain agents that inhibit blood clotting (medicines for thrombosis or to thin your blood, e.g., warfarin) − Azathioprine, 6-mercaptopurine or thioguanine (medicines used to treat immune disorders). Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should only use this medicine during pregnancy if your doctor tells you to. You should also only use this medicine during breast-feeding if your doctor tells you to, as this medicine and its metabolites may pass into breast milk. Driving and using machines There are no effects on the ability to drive and use machines. Mesalazine Dr Falk Pharma suppositories contain cetyl alcohol Cetyl alcohol may cause local skin reactions (e.g., contact dermatitis).
Mesalazine Dr Falk Pharma 500 mg suppositories Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Method of administration This medicine may only be used rectally, so it has to be inserted through the anus. Do NOT take by mouth. Dosage Adults and elderly: The recommended dose is one or two suppositories two to three times daily. Use in children
There is little experience and only limited documentation for an effect in children.
Duration of treatment The treatment of acute episodes of ulcerative colitis usually lasts 8 weeks. Your doctor will decide how long you need to continue the treatment with this medicine. This will depend on your condition. To obtain the maximum benefit from this medicine, you should use Mesalazine Dr Falk Pharma suppositories regularly and consistently, as directed. If you think your Mesalazine Dr Falk Pharma suppositories are too strong or too weak, talk to your doctor. If you use more Mesalazine Dr Falk Pharma suppositories than you should Contact a doctor if you are in doubt, so he or she can decide what to do. If you use too many suppositories on one occasion, just use your next dose as prescribed. Do not use a smaller amount. If you forget to use Mesalazine Dr Falk Pharma suppositories Do not use a larger than normal dose of Mesalazine Dr Falk Pharma suppositories next time, but continue treatment at the prescribed dosage. If you stop using Mesalazine Dr Falk Pharma suppositories Do not stop using this product until you have talked to your doctor. If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any of the following symptoms after taking this medicine, you should contact your doctor and stop using Mesalazine Dr Falk Pharma suppositories immediately: − General allergic reactions such as skin rash, fever, joint pain and/or breathing difficulties or a general inflammation of your large bowel (causing severe diarrhoea and abdominal pain). These reactions are very rare. − A marked reduction of your general health, especially if accompanied by fever, and/or a sore throat and mouth. These symptoms can, very rarely, be due to a fall in the number of white cells in your blood, which may make you more prone to developing a serious infection (agranulocytosis). Other cells of the blood may also be affected (e.g., platelets or red cells causing aplastic anaemia or thrombocytopenia) and cause symptoms which may include unexplained bleeding, purple spots or patches under your skin, anaemia (feeling tired, weak and looking pale, especially on lips and nails). A blood test can confirm whether your symptoms are due to an effect of this medicine on your blood. These reactions are very rare. − Serious skin rashes with reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, widespread rash, fever and enlarged lymph nodes. These can be preceded by fever and flulike symptoms. These reactions occur in an unknown number of patients (frequency not known). − Shortness of breath, chest pain or irregular heartbeat, or swollen limbs which may be indicative of cardiac hypersensitivity reactions. These reactions are rare.
− –
Problems with your kidney function (can occur very rarely), e.g., a change in the colour or amount of urine produced and swollen limbs or a sudden flank pain (caused by a kidney stone) (occur in an unknown number of patients (frequency not known)). Strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears. These could be symptoms of increased pressure within your skull (idiopathic intracranial hypertension) (frequency not known [cannot be estimated from the available data]).
The following side effects have also been reported by patients using mesalazine: Common: may affect up to 1 in 10 patients − Rash, itching Rare side effects (that affect less than 1 in 1,000 patients) − Abdominal pain, diarrhoea, wind (flatulence), nausea and vomiting, constipation − Headache, dizziness − Increased sensitivity of your skin to sun and ultraviolet light (photosensitivity) Very rare side effects (that affect less than 1 in 10,000 patients) − Changes in kidney function, sometimes with swollen limbs or flank pain − Severe abdominal pain because of acute inflammation of the pancreas − Shortness of breath, cough, wheezing, lung shadow on x-ray due to allergic and/or inflammatory lung conditions − Muscle and joint pain − Jaundice or abdominal pain because of liver or bile flow disorders − Hair loss and the development of baldness − Numbness and tingling in the hands and feet (peripheral neuropathy) − Reversible decrease in semen production
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store By reporting side effects you can help provide more information on the safety of this medicine.
Mesalazine Dr Falk Pharma 500 mg suppositories Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister strip and on the carton. The expiry date refers to the last day of that month. Do not store above 30C. Store in the original container in order to protect contents from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
What Mesalazine Dr Falk Pharma suppositories contain The active substance is mesalazine and one suppository contains 500mg mesalazine. The other ingredients are Hard fat, docusate sodium, cetyl alcohol.
What Mesalazine Dr Falk Pharma suppositories look like and contents of the pack Mesalazine Dr Falk Pharma suppositories are in white opaque PVC/PE strips of 5. Available in packs of 10 or 30 suppositories. Not all packs may be marketed. Marketing Authorisation Holder Dr Falk Pharma UK Ltd Unit K, Bourne End Business Park, Cores End Road Bourne End, SL8 5AS Tel: 01628 536600 e-mail: [email protected] Manufacturer Dr. Falk Pharma GmbH Leinenweberstrasse 5, 79108 Freiburg, Germany This leaflet was last revised in 04/2025.
Mesalazine Dr Falk Pharma 500mg suppositories (previously known as Salofalk) comes as suppository containing 500mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Mesalazine Dr Falk Pharma 500mg suppositories (previously known as Salofalk) is mesalazine.
This leaflet reproduces the patient information leaflet approved for Mesalazine Dr Falk Pharma 500mg suppositories (previously known as Salofalk), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Management of mild and moderate episodes of ulcerative colitis that is limited to the rectum.
Posology
Adults and the Elderly: 1 to 2 suppositories, 2 to 3 times daily.
The dosage should be adjusted to suit the progress of the condition. Do not discontinue treatment suddenly.
Paediatric population: There is little experience and only limited documentation for an effect in children.
Method of administration:
Rectal
The treatment of acute episodes of ulcerative colitis usually lasts 8 weeks
Mesalazine Dr Falk Pharma suppositories are contraindicated in cases of:
Hypersensitivity to the active substance, salicylates or to any of the excipients listed in section 6.1.
Severe impairment of renal or hepatic function.
Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip-sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4 weeks.
If the findings are normal, follow-up tests should be carried out every 3 months. If additional symptoms occur, these tests should be performed immediately.
Caution is recommended in patients with impaired hepatic function.
Mesalazine should not be used in patients with impaired renal function. Mesalazine-induced renal toxicity should be considered if renal function deteriorates during treatment. If this is the case, Mesalazine Dr Falk Pharma suppositories should be discontinued immediately.
Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.
Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).
Serious blood dyscrasias have been reported very rarely with mesalazine. Hematological investigations should be performed if patients suffer from unexplained haemorrhages, bruises, purpura, anaemia, fever or pharyngolaryngeal pain. Mesalazine Dr Falk Pharma suppositories should be discontinued in case of suspected or confirmed blood dyscrasia.
Cardiac hypersensitivity reactions (myocarditis, and pericarditis) induced by mesalazine have been rarely reported. Mesalazine Dr Falk Pharma suppositories should then be discontinued immediately.
Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment with mesalazine.
Severe cutaneous adverse reactions
Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.
Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.
Idiopathic intracranial hypertension
Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered.
Patients with a history of adverse drug reactions to preparations containing sulphasalazine should be kept under close medical surveillance on commencement of a course of treatment with mesalazine. Should the suppositories cause acute intolerance reactions such as abdominal cramps, acute abdominal pain, fever, severe headache and rash, therapy should be discontinued immediately.
Mesalazine Dr Falk Pharma suppositories contain cetyl alcohol. Cetyl alcohol may cause local skin reactions (e.g. contact dermatitis).
Specific interaction studies have not been performed.
In patients who are concomitantly treated with azathioprine,6-mercaptopurine or thioguanine a possible increase in the myelosuppressive effects of azathioprine, 6-mercaptopurine or thioguanine should be taken into account.
There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.
Fertility
There are no adequate data from the use of mesalazine in pregnant women. However, data on a limited number of exposed pregnancies indicate no adverse effect of mesalazine on the pregnancy or on the health of the foetus/newborn child. To date no other relevant epidemiologic data are available. In one single case after long-term use of a high dose mesalazine (2-4g/day, orally) during pregnancy, renal failure in a neonate was reported.
Animal studies on oral mesalazine do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development.
Pregnancy
Mesalazine Dr Falk Pharma suppositories should only be used during pregnancy if the potential benefit outweighs the possible risk.
Breast-feeding
N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. Only limited experience during lactation in women is available to date. Hypersensitivity reactions such as diarrhoea in the infant cannot be excluded. Therefore, Mesalazine Dr Falk Pharma suppositories should only be used during breast-feeding if the potential benefit outweighs the possible risk. If the infant develops diarrhoea, breast-feeding should be discontinued.
Mesalazine has no or negligible influence on the ability to drive and use machines.
Organ Class System
Frequency According to MedDRA convention
Common
(≥ 1/100; <1/10)
Rare
(≥ 1/10,000; <1/1,000)
Very rare
(< 1/ 10,000)
Not known
(cannot be estimated from the available data)
Blood and lymphatic system disorders
Altered blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia)
Nervous system disorders
Headache, dizziness
peripheral neuropathy
Idiopathic intracranial hypertension (see section 4.4)
Cardiac disorders
Myocarditis, Pericarditis
Respiratory, thoracic and mediastinal disorders
Allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis)
Gastrointestinal disorders
Abdominal pain, diarrhoea, flatulence, nausea, vomiting, constipation
Acute pancreatitis
Renal and urinary disorders
Impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency
Nephrolithiasis*
Skin and sub-cutaneous tissue disorders
Rash, pruritus
Photosensitivity
Alopecia
Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)
Musculo-skeletal and connective tissue disorders
Myalgia, arthralgia
Immune system disorders
Hypersensitivity reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis
Hepato-biliary disorders
Changes in liver function parameters (increase in transaminases and cholestasis parameters), hepatitis, cholestatic hepatitis
Reproductive system disorders
Oligospermia (reversible)
* see section 4.4 for further information
Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).
Photosensitivity
More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store
There are rare data on overdosage (e.g., intended suicide with high oral doses of mesalazine), which do not indicate renal or hepatic toxicity. There is no specific antidote and treatment is symptomatic and supportive.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Mesalazine Dr Falk Pharma 500mg suppositories (previously known as Salofalk). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.